Guide for Authors

  • Overview
    In addition to general articles on clinical aspects of diabetes mellitus, Diabetes and Metabolic Syndrome: Clinical Research and Reviews also presents articles on basic research in all areas of diabetes and the metabolic syndrome. Topics include prevention, diagnosis, pathogenesis, clinical management of diabetes and all its complications, including neuropathy, retinopathy, nephropathy, peripheral vascular disease, foot problems (amongst others), as well as atherosclerotic cardiovascular disease. All aspects of disorders associated with the metabolic syndrome with a special emphasis on clinical aspects (prevalence, pathogenesis, risk factors management and prevention, etc.) of comorbid conditions such as hypertension, obesity, dyslipidemias and atherosclerotic cardiovascular disease are also of relevance to the journal. Diabetes and Metabolic Syndrome: Clinical Research and Reviews also publishes papers on the general pathogenesis and prevention of diabetes.

    Criteria for initial considerations for papers submitted will be originality, statistical rigour, and relevance to the aims of the journal. All manuscripts of interest will be subjected to the process of peer review. Initially all submissions are reviewed internally by members of the Editorial Board and all submissions which pass this stage are then subjected to an external peer-review process. Please include names and contact details for six individuals as suggested reviewers for the manuscript, for use at the Editors' discretion.

    Journal Principles
    All manuscripts submitted to Diabetes and Metabolic Syndrome: Clinical Research and Reviews should report original research not previously published or being considered for publication elsewhere, make explicit any conflict of interest, identify sources of funding and generally be of a high ethical standard.

    Submission of a manuscript to this journal gives the publisher the right to publish that paper if it is accepted. Manuscripts may be edited to improve clarity and expression. Submission of a paper to Diabetes and Metabolic Syndrome: Clinical Research and Reviews is understood to imply that it has not previously been published and that it is not being considered for publication elsewhere.

    Work on human beings that is submitted to the journal should comply with the principles laid down in the Declaration of Helsinki "Recommendations guiding physicians in biomedical research involving human subjects", adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964 (and its successive amendments). The manuscript should contain a statement that the work has been approved by the appropriate ethical committees related to the institution(s) in which it was performed. Studies involving experiments with animals must state that their care was in accordance with institution guidelines.

    Patients and Study Participants
    Studies on patients or volunteers require ethics committee approval and informed consent which should be documented in your paper.

    Patients have a right to privacy. Therefore identifying information, including patient's photographs, pedigree, images, names, initials, or hospital numbers, should not be included in the submissions unless the information is essential for scientific purposes and written informed consent has been obtained for publication in print and electronic form from the patient (or parent, guardian or next of kin ). If such consent is made subject to any conditions, Elsevier must be made aware of all such conditions. Written consents must be provided to the journal on request.

    Even where consent has been given, identifying details should be omitted if they are not essential. Complete anonymity is difficult to achieve. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

    Clinical Trials
    All randomised controlled trials submitted to Diabetes and Metabolic Syndrome: Clinical Research and Reviews whose primary purpose is to affect clinical practice (phase 3 trials) must be registered in accordance with the principles outlined by the International Committee of Medical Journal Editors (ICMJE; ICJME-approved registries currently include the following: ''; ''; ''; ''; and ''. Please include the unique trial number and registry name on manuscript submission.

    Conflict of Interest
    Authors are required to disclose commercial or similar relationships to products or companies mentioned in or related to the subject matter of the article being submitted. Sources of funding for the article should be acknowledged in a footnote on the title page. Affiliations of authors should include corporate appointments relating to or in connection with products or companies mentioned in the article, or otherwise bearing on the subject matter thereof. Other pertinent financial relationships, such as consultancies, stock ownership or other equity interests or patent-licensing arrangements, should be disclosed to the Editor-in-Chief in the cover letter at the time of submission. Such relationships may be disclosed in the Journal at the discretion of the Editor-in-Chief.

    Article Types
    i. Editorials are either written or commissioned by the Editors and should not exceed 1000 words (not including a maximum of 20 references; one small figure can be included).

    ii. Commentaries (1000 words not including a maximum of 20 references and one small figure) offer a stimulating, journalistic and accessible insight into issues of common interest. They are usually commissioned by the Editors but unsolicited articles will be considered. Debates comprise two commentaries of opposing or contrasting opinion written by two different groups of authors. Controversial opinions are welcomed as long as they are set in the context of the generally accepted view.

    iii. Original Research Articles should be a maximum of 5000 words. The word limit includes a maximum of five figures or tables with legends, but does not include up to 50 references and an abstract of up to 200 words structured according to Aims, Methods, Results, Conclusions and Keywords. Divide the manuscript into the following sections: Title Page; Structured Abstract; Introduction; Subjects, Materials and Methods; Results; Discussion; Acknowledgements; References; figures and tables with legends.

    iv. Brief Reports should not exceed 1000 words, including a summary of no more than 50 words (but not including up to 20 references) and may be a preliminary report of work completed, a final report or an observation not requiring a lengthy write-up.

    v. Review articles should be a maximum of 5000 words, including a summary of no more than 100 words (not including up to 75 references) with subheadings in the text to highlight the content of different sections. Reviews are generally commissioned by the Editors but unsolicited articles will be considered.

    vi. Letters to the Editor should be no more than 400 words.

    Manuscript Submission
    Manuscripts may be submitted online or directly to the Editor-in-Chief by e-mail or traditional mail.

    Please submit manuscripts online at and the instructions on the site should be followed closely. Authors can track manuscript progress to final decision. Reviewers can download manuscripts and submit their reports to the Editors.

    For those who cannot submit online, manuscripts should be typewritten, double-spaced, using a standard sized typeface and margins of at least one inch. Place insert two carriage returns after every element, such as title, headings, paragraphs, and figure and table callouts. Please submit with electronic files to the Editor-in-Chief:

    Dr S.M. Sadikot
    50, Manoel Gonsalves Rd.,
    Bandra (W),
    Mumbai 400050
    Phone: +919820045859
    (Alternative email:

    Title Page
    On the title page, include title; subtitle (if any); first name, middle initial, and last names of each author, with academic degrees; name of Department(s) and Institution(s) to which the work should be attributed; name and address of author to whom requests for reprints should be sent. The address, telephone and fax numbers of the person responsible for negotiations concerning the manuscripts should be listed separately and clearly labelled as such. Authors will be required to sign a statement conferring the manuscript copyright to Diabetes and Metabolic Syndrome: Clinical Research and Reviews.

    Abstract and Keywords
    A structured abstract of 100 to 250 words for articles (including Reviews), or 50 to 100 words for Brief Communications, should be provided. It should cover the main factual points, including statements of the problem, methods, results, and conclusions. The abstract should be accompanied by a list of three to five keywords for indexing purposes.

    Main Text
    Headings and subheadings should be provided in the Methods and Results sections, and where appropriate in the discussion. Please keep the text clear, concise and free of jargon.

    Abbreviations, Numbers and SI Units
    Authors should limit the use of abbreviations. Terms which are mentioned frequently may be abbreviated but only if this does not detract from reader comprehension. The abbreviation should be defined after the first use of the term.

    Measurements of length, height, weight and volume should be reported in metric units. Temperatures should be given in degrees Celsius and blood pressures in millimetres of mercury or kPa with the alternative unit in parentheses. All other measurements including laboratory measurement should be reported in the metric system in terms of the International System of Units (SI).

    Drug Names
    Generic names should be used. Proprietary names may be given (parenthetically) with the first use of the generic name.

    References should be numbered consecutively (with square brackets) as they appear in the text. The reference list should be in the form shown by the three examples below.

    [1] The F DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-21.
    [2] J.L. Chiasson, R. Gomis, M. Hanefeld, R.G. Josse, A. Karasik, M. Laakso. The STOP-NIDDM trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Diabetes Care 1998;21:1720-5.
    [3] R.E. Pratley, C. Weyer. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001;44:929-45.

    Please note that all authors should be listed when three or fewer; when four or more, list only the first three and add et al. Do not include references to personal communications, unpublished data or manuscripts either in preparation or submitted for publication. If essential, such material may be incorporated into the appropriate place in the text. Titles of journals should be abbreviated according to MEDLINE (National Library of Medicine). Recheck references in the text against the reference list before your manuscript is accepted. The accuracy of references is the responsibility of the author.

    Tables should be numbered consecutively with Arabic numerals. Provide a short descriptive heading and explanation above each table with a legend. Symbols for units should be confined to column headings. Abbreviations should be kept to a minimum, and when used, explained fully.

    Figures must be suitable for high-quality reproduction. Lettering should be complete, of professional quality, and of a size appropriate to that of the illustration or drawing, with the necessary reduction in size taken into account. If, together with your accepted article, you submit usable colour figures, Elsevier will ensure that these figures appear free-of-charge in colour in the electronic version of your accepted article. Colour illustrations can only be included in print if the additional cost of reproduction is contributed by the author: you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please go to and click on the Artwork Guidelines.

    Supplementary Files
    Authors may submit additional supportive applications, movies, animation sequences, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier web products, including ScienceDirect: In order to ensure that your submitted material is directly usable, please ensure that data is provided in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file.

    The language of the journal is English. Upon request, Elsevier will direct authors to an agent who can check and improve the English of their paper (prior to submission). Please contact for further information.

    Publisher Services
    Proofs will be sent to the authors for careful checking. Corrected proofs should be returned to the publisher within stated deadlines.

    Elsevier will do everything possible to get your article corrected and published as quickly and accurately as possible. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication. Subsequent corrections will not be possible, so please ensure your communication is complete.

    Fast-track Publication: The journal aims for prompt publication of all accepted papers. Submissions containing new and particularly important data may be fast-tracked for peer review and publication; this is a limited facility and is strictly at the discretion of the Editors.

    Page Charges are not made.

    Offprints/Reprints. The corresponding author, at no cost, will be provided with a PDF file of the article. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use. Paper offprints can be ordered by the authors. An order form with prices will be sent to the corresponding author.

    Special Subject Repositories Certain repositories such as PubMed Central ('PMC') are authorized under special arrangement with Elsevier to process and post certain articles. The following agreements have been established for authors whose articles have been accepted for publication in an Elsevier journal and whose underlying research is supported by one of the following funding bodies:
    o National Institutes of Health: Elsevier will send a version of the author's accepted manuscript that includes author revisions following peer-review for public access posting 12 months after final publication. Because the NIH 'Public Access' policy is voluntary, authors may elect not to deposit such articles in PMC. If you wish to 'opt out' and not deposit to PMC, you may indicate this by sending an e-mail to More information regarding the agreement between Elsevier and the National Institutes of Health can be found at
    o The Wellcome Trust: Elsevier will send to PMC the version of the author's manuscript that reflects all author-agreed changes including those made post peer review, for public access posting immediately after final publication. Authors are required to initially subsidize their manuscript with fees reimbursed by the Wellcome Trust. Wellcome Trust authors, whose manuscripts are subsidized, will have the corresponding articles made free to non-subscribers on ScienceDirect and Elsevier's electronic publishing platforms. More information regarding the agreement between Elsevier and The Wellcome Trust can be found at


advert image